Plus   Neg

Moleculin Biotech Inc. (MBRX) Has Climbed To Over A 4-Month High

Moleculin Biotech Inc. (MBRX) announced Thursday morning that it has developed and licensed a potential major breakthrough new cancer treatment that selectively kills highly resistant tumors.

Moleculin Biotech gapped open sharply higher this morning and is now up 0.98 at $2.80 with volume at a 6-month high. The stock has risen to over a 4-month high.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT